Fennec Pharmaceuticals Inc
FENC
Get informed when a big investor buys or sells
+ FollowMarket Cap$354.32M
Close$
$-9.74
195.5% downside
Current Fair Value
195.5% downsideOvervalued by 195.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $354.32 Million |
|---|---|
| Enterprise Value | $316.25 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.36 |
| Beta | 1.1 |
| Outstanding Shares | 34,545,000 |
Return
| Return on Equity | -8.69% |
|---|---|
| Return on Assets | -4.87% |
| Return on Invested Capital | -2.70% |
Valuation & Multiples
| P/E Ratio | -78.46 |
|---|---|
| PEG | 48.26 |
| Price to Sales | 10.2 |
| Price to Book Ratio | 10.2 |
| Enterprise Value to Revenue | 5.32 |
| Enterprise Value to EBIT | -184.9 |
| Enterprise Value to Net Income | -86 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$16.21 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$19.11 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 35,200▲ 57.14% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 47.44%▲ 0.26% |
|---|---|
| Total Invested | $175.86M▲ 76.50% |
| Investors Holding | 109▲ 18.00% |
ESG Score
No data
About Fennec Pharmaceuticals Inc
CEO: Rostislav Raykov